Buspirone Shortage In Healthcaristan SSR

A 'reverse voxsplaining' deep-dive on why drugs run short / cost too much. Part I: the national buspirone shortage (the FDA shut a dirty Mylan plant making 1/3 of supply; generics are consolidated). Why do drug shortages happen when bread/chairs don't? His answer is the GDUFA generic-drug fees: a flat per-factory fee that doesn't scale with output (a regressive tax favoring monopolies/concentration), plus fees on idle approvals — so companies cancel old approvals, destroying the latent-competition safety-valve that used to deter Shkrelis. Part II: insulin — a 'biologic' (a ~700-atom peptide), so biosimilars cost $100M+ and 8-10 years vs $1-5M for small-molecule generics; brand 'patent thickets' (Sanofi's 74 Lantus patents) and the different-name rule choke competition. The gotcha: Peru has cheap biosimilar insulin, so the US problem is regulatory — 'the government will shoot anyone who tries to make cheap insulin.' Concludes the system needs structural reform, not Vox's 'more government.'

Quality 75 · Excellent. 75 — Excellent floor. A sharp, well-researched, memorable policy explainer that does real explanatory work nobody else laid out clearly (GDUFA's monopoly-favoring fee structure; biologics as regulatory natural-monopolies; the Peru comparison). Self-described as tentative and bounded to drug markets, which keeps it at the floor.

Claude’s paradigm shift 56 · Moderate. 56 — Major-shift edge. The GDUFA-fee-structure + biologic-regulation explanation for shortages/high prices was a fresh, non-obvious synthesis against the usual 'greed'/'free market' stories.

Real-world impact 3 · Moderate. 3 — an influential healthcare-economics 'reverse voxsplaining' piece cited within the policy-discourse sphere; no direct material effect.